Beyond Animal Health: How Hester’s March-Quarter Numbers Translate Into A Solid Rs 11 Payout

The dividend proposal reflects management’s confidence in cash flows and earnings visibility, even as the company continues to invest in capacity, R&D and new product lines. For investors, the combination of profit growth and a steady payout signals a balance between rewarding shareholders and funding future expansion in domestic and export markets.

March Quarter Performance Snapshot

Hester’s March-quarter consolidated revenue from operations came in at about 1 billion rupees, supported by continued demand for animal health products and vaccines. The company’s consolidated net profit stood at 159.8 million rupees, underscoring resilient margins despite input cost and regulatory pressures in the broader pharma and biotech space.

Dividend Proposal And Investor Takeaways

The board has recommended a dividend of 11 rupees per share for FY 2025-26, subject to shareholder approval at the upcoming AGM. For long-term investors, this implies a reasonable payout on top of capital appreciation potential, while also indicating that the balance sheet is strong enough to sustain both growth investments and regular dividends.

Hester Biosciences Key Highlights

• Proposed dividend of 11 rupees per share for FY 2025-26
• March-quarter consolidated revenue from operations at around 1 billion rupees
• March-quarter consolidated net profit at 159.8 million rupees
• Signals confidence in earnings quality and future growth prospects
• Shows balanced capital allocation between dividends and business expansion

Sources: Rediff Money, BlinkX, Business Standard, MoneyControl, ScanX, MarketsMojo